The FDA granted 510(k) clearance and a CLIA waiver to Diasorin’s Liaison Nes multiplex group A streptococcus test, the company said. The assay is designed for rapid point-of-care use, delivering results in about 15 minutes with less than one minute of hands-on time. Diasorin said the test reagents can be stored at room temperature and that the compact, cloud-connected Nes platform supports real-time reporting for outpatient and decentralized settings. Company executives positioned the addition as the second assay on the Nes system, following FDA clearance and CLIA waiver for its respiratory panel covering influenza A, influenza B, RSV, and COVID-19 in December. In parallel, Diasorin noted that a customizable gastrointestinal panel on Liaison Plex also received FDA clearance in May. Diasorin previously laid out goals for the Nes system to generate more than $150 million in U.S. revenue by 2030.